EsoCap cooperated with Zühlke Engineering, Schlieren near Zurich, to develop the entire process of transforming the initial manual production of EsoCap's first product, ESO-101, into an automated production line. State-of-the-art…
Presentation of the ACESO-Trial Design, a randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability, and safety of a novel delivery system (ESO-101) for topical esophageal treatment. ESO-101, EsoCap’s lead product…
EsoCap AG has been featured in Fierce Pharma Online. “We are extremely pleased that Fierce Pharma Online reviewed EsoCap’s unique and innovative topical drug delivery system to the esophagus and…
EsoCap AG has received Orphan Drug Designation from the United States Food & Drug Administration (FDA) for use of ESO-101 in the treatment of EoE (eosinophilic esophagitis). “We are pleased…
EsoCap AG organized a multidisciplinary scientific advisory board meeting in Zurich with thirteen international experts on June 27, 2019. As an introduction, Prof. Werner Weitschies, Center for Drug Absorption and…
EsoCap AG announced that a capital increase has been authorized by the Extraordinary General Assembly, held on April 11, 2019, followed by successful completion of a private placement financing. The…
EsoCap AG is one of just a handful of companies in the area of biotech and medtech selected to present at the Bio-Europe conference start-up spotlight on March 26th, 2019 in Vienna.
Basel, Switzerland, February 6, 2019 EsoCap AG and LTS Lohmann Therapy-Systeme AG announced the start of cooperation on industrial development of a unique drug delivery technology for diseases of the…
Basel, Switzerland, July 13th, 2018 EsoCap AG announced that it has successfully completed a private placement financing round on July 13th, 2018. The proceeds of the capital increase will be…
EsoCap AG organized a scientific advisory board meeting with eight international experts in Eosinophilic Esophagitis (EoE) in Zürich on June 14th, 2018. Prof. Dr. Werner Weitschies, Head of the Center of Drug Absorption and Transport at the University of Greifswald gave a keynote presentation on EsoCap’s unique drug delivery platform.
Malzgasse 9, CH-4052 Basel
